Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields
- 1 January 1994
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 13 (3) , 177-181
- https://doi.org/10.3109/02713689408995775
Abstract
We investigated the ability of liposomes to deliver the immunosuppressive agent cyclosporine A (CsA) to the cornea, anterior sclera, aqueous humor, and vitreous in rabbit eyes. One drop (10 μl) of liposome-encapsulated CsA (CsA-LIP) or olive oil drops containing an equivalent concentration of CsA (CsA-DR) were administered at 15-minute intervals within the first hour and then one hourly over a 6-hour period. In addition, collagen shields soaked for 30 minutes in the liposome preparation (CsA-LIP-CS) were tested in vitro and in vivo as a new drug delivery approach. CsA levels were measured by fluorescence-immunoassay after 1, 3, or 6 hours of drug administration. CsA levels in this study were highest in cornea and anterior sclera. In animals receiving either CsA-DR or CsA-LIP, CsA levels generally increased from 1 to 6 hours. In animals receiving a single application of CsA-CS-LIP, CsA levels peaked at 3 hours and declined at 6 hours in cornea and sclera. CsA-LIP and CsA-CS-LIP delivered significantly higher levels of CsA to the cornea and sclera at 1 and 3 hours than CsA-DR. In aqueous and vitreous humor, CsA levels increased from 1 to 6 hours in animals receiving either CsA-DR or CsA-LIP. On the other hand, animals receiving a single application of CsA-CS-LIP had lower levels of CsA at 6 hours than at the earlier time points. Animals receiving CsA-LIP or CsA-CS-LIP had significantly higher levels of CsA in aqueous and vitreous humor at 1, 3, and 6 hours than animals receiving CsA-DR. Moreover, animals receiving CsA-CS-LIP had higher CsA levels in aqueous humor at 1 and 3 hours than animals receiving CsA-LIP. CsA was not detectable in the serum of rabbits in any treatment group. These results demonstrate that liposome-encapsulated CsA is an effective means of intraocular drug delivery. The combination of liposome-encapsulated CsA with collagen shields may offer a new drug device for the eye.Keywords
This publication has 14 references indexed in Scilit:
- Prolongation of Corneal Allograft Survival with Liposome-encapsulated Cyclosporine in the Rat EyeOphthalmology, 1993
- EVIDENCE THAT LIPOSOME INCORPORATION OF CYCLOSPORINE REDUCES ITS TOXICITY AND POTENTIATES ITS ABILITY TO PROLONG SURVIVAL OF CARDIAC ALLOGRAFTS IN MICETransplantation, 1991
- A New Vehicle for Delivery of Cyclosporin A to the EyeCornea, 1990
- Liposome-bound cyclosporine: Aqueous and vitreous level after subconjunctival injectionInternational Ophthalmology, 1988
- Renal Histopathologic Alterations in Patients Treated with Cyclosporine for UveitisNew England Journal of Medicine, 1986
- Cyclosporine Penetration Into the Anterior Chamber and Cerebrospinal FluidAmerican Journal of Ophthalmology, 1985
- Penetration of Topical Cyclosporine Into the Rabbit Cornea, Aqueous Humor, and SerumArchives of Ophthalmology (1950), 1985
- Modulation of Experimental Autoimmune Uveitis With Cyclosporin AArchives of Ophthalmology (1950), 1982
- The preparation of large single bilayer liposomes by a fast and controlled dialysisBiochimica et Biophysica Acta (BBA) - Biomembranes, 1978
- A Collagenase Digestion Method for Bioassay of Antibiotics in Ocular TissuesAmerican Journal of Ophthalmology, 1978